NCT00265226View on ClinicalTrials.gov

Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

1,020

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Intra-dermal administration of Mycobacterium w

Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks

Trial Locations (8)

110029

All India Institute of Medical Sciences, New Delhi

110030

Lala Ram Swarup Institute of Tuberculosis and Respiratory Diseases, New Delhi

282001

Central JALMA Institute of Leprosy, Agra

380006

Smt NHL Municipal Medical College & B.J. Medical College, Ahmedabad

500004

Mahavir Hospital, Hyderabad

560 003

National Tuberculosis Institute, Bangalore

Unknown

SMS Medical College, Jaipur

600 031

Tuberculosis Research Centre, Chennai

All Listed Sponsors
lead

Ministry of Science and Technology, India

OTHER_GOV

NCT00265226 - Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients | Biotech Hunter | Biotech Hunter